talimogene laherparepvec

FDA Drug Profile — Imlygic

talimogene laherparepvec is listed in the FDA National Drug Code directory with 6 NDC codes, marketed under brand name including Imlygic. Available dosage form: injection, suspension.

Drug details

Generic Name
talimogene laherparepvec
Brand Names
Imlygic
Application Number
BLA125518
Sponsor
IDT Biologika GmbH
NDC Codes
6
Dosage Forms
INJECTION, SUSPENSION
Routes
INTRALESIONAL
Active Ingredients
TALIMOGENE LAHERPAREPVEC

Indications and Usage

1 INDICATIONS AND USAGE IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Limitations of use : IMLYGIC has not been shown to improve overall survival or have an effect on visceral metastases. IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Limitations of use : IMLYGIC has not been shown to improve overall survival or have an effect on visceral metastases. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.